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Infectious diseases form one of the great-
est global challenges in medicine in our
time. Ever since the famous, wrong pre-
diction of the Surgeon General of the
United States, William H. Stewart, in
1969: “We can close the books on infec-
tious diseases,” infectious diseases have
been on the rise. A large number of new
infectious diseases emerged: major threats
to the world like AIDS and SARS, but
also less threatening infections, like those
caused by Campylobacter spp, Borrelia
spp, Bartonella henselae, Clostridium dif-
ficile, Hanta viruses. These have led to
major changes in clinical practice, micro-
biology services, public health activities,
and biomedical research.
Not only new infectious agents, but also
known microorganisms have appeared
that acquired new virulence (e.g., the
group A streptococcus, and Staphylococcus
aureus, both causing toxic shock syn-
drome, the Beijng type of Mycobacterium
tuberculosis) or new antimicrobial resis-
tance (such as extended-spectrum beta-
lactamase and carbapenemase producing
Gram-negative bacteria, vancomycin-
resistent Gram-positive bacteria and
multi-drug resistant Mycobacteria and
drug-resistant Plasmodia). The emerg-
ing infections reflect the versatile nature
of the organisms within the microbial
world, and they represent major chal-
lenges that will continue to arise for those
engaged in research of infectious diseases.
This research should not only deal with
the mechanisms of microbial plasticity,
but also with entirely new ways of inter-
vention, i.e., therapy and prevention. In
addition, scientific input is also necessary
in epidemiology, including surveillance,
early warning and response. With regard
to outbreak management, the areas of
logistics, decision-making and communi-
cation to professionals and to the public
have been neglected fields of research. The
infectious diseases that occur in the con-
text of poverty form a great challenge.
How can we prevent and treat these in
an affordable fashion, thereby breaking
the cycle of disease, lack of income and
increase of poverty, poor living conditions
and increased susceptibility to infection?
since we know far too little of the patho-
physiology of infectious diseases, this is an
area of great interest for Frontiers. How
do microorganisms adapt to the microen-
vironment at different body sites? How
do microorganisms and the defence of
the host modulate in time, in response
to each other? Is it possible to obtain
real-time information about the state of
this war, to guide therapy in clinical
medicine? Our in-vivo imaging techniques
lack discriminative power to obtain this
kind of information. Also, our modali-
ties for intervention are limited and rather
primitive, mainly derived from traditional
in-vitro studies. From new insights in
pathogenesis of infection, new diagnos-
tic approaches and perhaps new therapies
may be derived.
During the past half-century, we dis-
posed of a variety of antimicrobial drugs
that really changed the prognosis of infec-
tious diseases in many parts of the world.
However, largely by indiscriminate medi-
cal and veterinary use of these marvellous
drugs, a huge selective pressure has been
exerted on the microbial flora that col-
onizes humans and animals, as well as
on the environmental microbes. In the
gloomiest scenario, we will be arriving at a
situation that is similar to that of the pre-
antibiotic era (1). Interestingly, the antimi-
crobial resistance is not homogeneously
spread over the world. Some countries,
like the Netherlands and the Scandinavian
countries have less severe antimicrobial
resistance problems than other countries.
Although the reasons for these differ-
ences are multi-factorial, a main rea-
son is the prudent use of antibiotics
in these countries. Research is needed
to better understand the determinants
of antibiotic usage in different coun-
tries and to come up with methods to
change prescribing behavior and patient
demand (2).
As resistance to the existing drugs is
rapidly increasing, the stagnant develop-
ment of new antibiotics is of great con-
cern. The tragedy here is that, on the one
hand, the classical techniques of antibiotic
development that were highly effective in
“the golden age of antibiotic discovery”
have been abandoned, while, on the other
hand the promises of genomic approaches,
so far, have not come true (3). In fact,
the latter approaches have not led to
useful drugs. Do we have to return to
the old strategies of antibiotic discovery,
using natural resources? There must be
sources of antimicrobial (such as plants,
marine organisms) that have not been fully
explored. But we also need entirely new
approaches to combat infection. In this
respect, it is tragic that industry lost inter-
est in antibiotics, because of the enormous
costs of development and the relatively low
chance of return of investment with antibi-
otics (because they are prescribed mainly
in short courses). Here, new strategies,
not only in the scientific approach, but
also regarding reimbursement incentives
are needed.
Another area of tragedy is the immuno-
therapy of infectious diseases. First of all,
all interventions that aim to interfere with
the deleterious cytokinemia in sepsis (like
antibodies and inhibitors against tumour
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necrosis factor (TNF), and interleukin-1
receptor antagonist) failed in randomized
controlled clinical trials. Why this is, is
speculative, but to my mind the follow-
ing factors—in combination—play a role.
First of all sepsis is not one entity. In the
past decades, the SIRS (severe inflamma-
tory response syndrome) and sepsis con-
cept as proposed by the late Roger Bone
was considered one kind of cytokine dis-
order (4) in which severity was largely
due to the concentrations of deleteri-
ous cytokine such as TNF. Non-infectious
and infectious causes of SIRS and sep-
sis were thought to be very similar if
not equal regarding the pathophysiological
events. This is clearly an oversimplifica-
tion and the complexity of the cytokine
networks was clearly underestimated. For
instance, sepsis arising from an infec-
tious focus in the abdomen is different
from that in other body sites; recent data
obtained with systems biology indicate
that different microorganisms differ with
regard to the complex cytokine pathways
(“signature”) that are being induced (5).
Hence certain strategies may work for
some microorganisms, while being dele-
terious for others. On the other side of
the coin, human hosts may also differ in
the magnitude and the pattern of their
responses. This would mean that certain
interventions do not work in all patients.
Also, the concept of “non-microbial sep-
sis” has to be revisited with modern tech-
niques, to see whether this is a real entity
and to what extent it differs from what
infectious disease physicians would coin
as sepsis.
Especially in the large clinical trials on
sepsis intervention, the heterogeneity of
the patients probably has contributed to
the poor outcome of these trials. Another
serious problem was the poor execu-
tion of these mega-trials, with regard to
inclusion of patients (6). Without doubt,
this has harmed quite a number of new
drugs. Another point here is that the
mega trials were started before a good
assessment of the biological effects of the
intervention was done. It has become
clear that for instance the administration
of anakinra (recombinant interleukin-1
receptor antagonist) was too short, as
rebounds were seen after cessation of
the drug.
We also embarked on these trials,
before it was clear that the proinflamma-
tory state in sepsis was rapidly followed
by an anti-inflammatory mode (nowadays
called “immunoparalysis”) (7, 8). Most
interventions were aimed at the proin-
flammatory state, and did not take into
account this second phase. In fact, cur-
rently the attention seems to be directed
to the second phase only. It is clear
that we need better descriptions of the
mediators and of the sequence of events
in the various life-threatening infections.
Thus, interventional RCTs (randomized
controlled clinical trials) remain a chal-
lenge in this field, but are feasible in well-
defined patient groups; the clarithromycin
RCT in septic patients with ventilator-
associated pneumonia is a good exam-
ple (9). Other interventions in carefully
defined sepsis patients that are amenable
for investigation are interferon-g, and
granulocyte macrophage colony stimulat-
ing factor treatment.
This brings us to the next challenge.
Despite the fact that we have safe recombi-
nant cytokines that are capable to enhance
host defence, such as interferon-g, granu-
locyte colony stimulating factor and gran-
ulocyte macrophage colony stimulating
factor—with a few exceptions—we do not
have solid evidence when to use these
drugs in patients. Given the rarity of con-
ditions in which these drugs may be useful
(e.g., refractory tuberculosis and other dif-
ficult to treat infections), it is difficult,
albeit not always impossible, to perform
RCTs (10). Apart from RCTs, we will have
to consider other methods to assess their
therapeutic potential and that of exciting
new immunomodulatory drugs that are
being developed.
Finally, a major area of success has been
the development of vaccines. Although
there are a series of effective and non-
toxic vaccines available, there are grand
challenges ahead, as we have not been
able to produce effective vaccines against
a number of severe infections (the most
prominent being HIV infection). More
knowledge of relevant vaccine epitopes,
of proper adjuvants and of the protective
immune response to candidate vaccines is
urgently.
In sum, we should be eager to read
the books on infectious diseases instead
of closing them; they are full of challeng-
ing unread pages, there to be explored. . .
By publishing exciting articles, Frontiers of
Infectious Diseases is ready to contribute
to this exploration!
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